Literature DB >> 15007105

Protective peptides that are orally active and mechanistically nonchiral.

Douglas E Brenneman1, Catherine Y Spong, Janet M Hauser, Daniel Abebe, Albert Pinhasov, Tania Golian, Illana Gozes.   

Abstract

Previous reports identified two peptides that mimic the action of neuroprotective proteins derived from astrocytes. These peptides, NAPVSIPQ and SALLRSIPA, prevent neuronal cell death produced by electrical blockade, N-methyl-d-aspartate, and beta-amyloid peptide (25-35). In the present study, all d-amino acid peptides of NAPVSIPQ and SALLRSIPA were synthesized and compared respectively to the corresponding all l-amino acid peptides. In rat cerebral cortical test cultures cotreated with 1 microM tetrodotoxin, the d-amino acid peptides produced similar potency and efficacy for neuroprotection as that observed for their respective l-amino acid peptides. Since all these peptides tested individually exhibited attenuation of efficacy at concentrations of >10 pM, combinations of these peptides were tested for possible synergies. Equimolar d-NAPVSIPQ and d-SALLRSIPA combination treatment produced potent neuroprotection (EC(50), 0.03 fM) that did not attenuate with increasing concentrations. Similarly, the combination of l-NAPVSIPQ and d-SALLRSIPA also had high potency (EC(50), 0.07 fM) without attenuation of efficacy. Combined administration of peptides was tested in a model of fetal alcohol syndrome and in a model of learning impairment: apolipoprotein E knockout mice. Intraperitoneal administration of d-NAPVSIPQ plus d-SALLRSIPA to pregnant mice (embryonic day 8) attenuated fetal demise after treatment with an acute high dose of alcohol. Furthermore, oral administration of d-NAPVSIPQ plus d-SALLRSIPA significantly increased fetal survival after maternal alcohol treatment. Apolipoprotein E knockout mice injected with d-NAPVSIPQ plus d-SALLRSIPA showed improved performance in the Morris water maze. These studies suggest therapeutic potential for the combined administration of neuroprotective peptides that can act through a mechanism independent of chiral recognition.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15007105     DOI: 10.1124/jpet.103.063891

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  20 in total

1.  Apolipoprotein E knockout mice as a model of behavioral dysfunction.

Authors:  Illana Gozes
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

2.  Generating orally active galanin analogues with analgesic activities.

Authors:  Charles R Robertson; Timothy H Pruess; Erin Grussendorf; H Steve White; Grzegorz Bulaj
Journal:  ChemMedChem       Date:  2012-02-28       Impact factor: 3.466

3.  NAP alpha-aminoisobutyric acid (IsoNAP).

Authors:  Illana Gozes; Yulie Schirer; Anat Idan-Feldman; Merav David; Sharon Furman-Assaf
Journal:  J Mol Neurosci       Date:  2014-01       Impact factor: 3.444

4.  Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial.

Authors:  Daniel A Leffler; Ciaran P Kelly; Peter H R Green; Richard N Fedorak; Anthony DiMarino; Wendy Perrow; Henrik Rasmussen; Chao Wang; Premysl Bercik; Natalie M Bachir; Joseph A Murray
Journal:  Gastroenterology       Date:  2015-02-13       Impact factor: 22.682

5.  Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL.

Authors:  Miri Holtser-Cochav; Inna Divinski; Illana Gozes
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

6.  Activity-dependent neuroprotective protein-derived peptide, NAP, preventing alcohol-induced apoptosis in fetal brain of C57BL/6 mouse.

Authors:  Y Sari
Journal:  Neuroscience       Date:  2008-11-21       Impact factor: 3.590

7.  Neurotrophic peptides, ADNF-9 and NAP, prevent alcohol-induced apoptosis at midgestation in fetal brains of C57BL/6 mouse.

Authors:  Youssef Sari; Jason M Weedman; Maxwell Nkrumah-Abrokwah
Journal:  J Mol Neurosci       Date:  2012-11-16       Impact factor: 3.444

8.  Understanding the mechanism of learning enhancement: NMDA and GABA receptor expression.

Authors:  Laura Toso; Andrea Johnson; Stephanie Bissell; Robin Roberson; Daniel Abebe; Catherine Y Spong
Journal:  Am J Obstet Gynecol       Date:  2007-09       Impact factor: 8.661

Review 9.  Neuroprotection against neurodegenerative diseases: development of a novel hybrid neuroprotective peptide Colivelin.

Authors:  Tomohiro Chiba; Ikuo Nishimoto; Sadakazu Aiso; Masaaki Matsuoka
Journal:  Mol Neurobiol       Date:  2007-02       Impact factor: 5.590

10.  NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42).

Authors:  Illana Gozes; Inna Divinski; Inbar Piltzer
Journal:  BMC Neurosci       Date:  2008-12-10       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.